专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2023012652A2 HYPOALLERGENIC PEANUT ALLERGENS, PRODUCTION AND USE THEREOF 审中-公开
公开(公告)号：WO2023012652A2
公开(公告)日：2023-02-09
申请号：PCT/IB2022/057144
申请日：2022-08-02
申请人： UKKO INC.
发明人： OFRAN, Yanay , BEN DAVID, Moshe , MARCU GARBER, Orly , NAFTALY KIROS, Si , DIAMANT, Gil , BREGMAN COHEN, Almog , KORMAN, Maayan , CHUPRIN, Anna , BIRON SOREK, Zohar , ROSENFELD SHLAMKOVICH, Lior , ROTEM, Etai , GAT, Yair
IPC分类号： A61K35/655
摘要： In one embodiment, the present disclosure provides hypoallergenic peanut allergens Ara h 1 or Ara h 2 variants lacking at least one epitope recognized by anti-Ara h 1 antibodies or anti-Ara h 2 antibodies, thereby having reduced or abolished antibody binding to the peanut allergen variants. These hypoallergenic peanut allergen variants may be used in methods of inducing desensitization to peanuts in a subject allergic to peanuts.

2. 发明申请

WO2022173534A1 SYSTEMS AND METHODS FOR IMPROVING SOFT TISSUE CONTRAST, MULTISCALE MODELING AND SPECTRAL CT 审中-公开
公开(公告)号：WO2022173534A1
公开(公告)日：2022-08-18
申请号：PCT/US2022/011689
申请日：2022-01-07
申请人： ELUCID BIOIMAGING INC.
发明人： BUCKLER, Andrew J. , JI, Changguo , AYYAPILLAI, Murali
IPC分类号： G16H30/00
摘要： Systems and methods for improving soft tissue contrast, characterizing tissue, classifying phenotype, stratifying risk, and performing multi-scale modeling aided by multiple energy or contrast excitation and evaluation are provided. The systems and methods can include single and multi-phase acquisitions and broad and local spectrum imaging to assess atherosclerotic plaque tissues in the vessel wall and perivascular space.

3. 发明申请

WO2022159504A1 DEUTERATED CANNABINOID COMPOUNDS 审中-公开
公开(公告)号：WO2022159504A1
公开(公告)日：2022-07-28
申请号：PCT/US2022/012997
申请日：2022-01-19
申请人： MERIT THERAPEUTICS, INC.
发明人： LAUFER, Ralph , SUMMA, Vincenzo
IPC分类号： A61K31/35 , A61K31/352 , C07D311/78 , C07D311/80
摘要： This invention relates to deuterated tetrahydrocannabinol compounds, deuterated tetrahydrocannabivarin compounds, deuterated cannabigerol compounds, and deuterated cannabichromene compounds, methods for preparation thereof, compositions comprising the same, and uses thereof for the treatment or prevention of numerous diseases or disorders including, but not limited to, fragile X syndrome, autism spectrum disorder, lysosomal storage diseases, leukodystrophies, Rett syndrome, osteoarthritis, musculoskeletal disorders, anorexia, emesis, pain, inflammation, multiple sclerosis, neurodegenerative disorders (Parkinson's disease, Huntington's disease, Alzheimer's disease), seizures, epilepsy, aggression, fear, phobias, anxiety, glaucoma, osteoporosis, schizophrenia, cardiovascular disorders, cancer, obesity, and metabolic syndrome-related disorders.

4. 发明申请

WO2022125585A1 TISSUE ORGANOID BIOPRINTING AND HIGH-THROUGHPUT SCREENING METHODOLOGY 审中-公开
公开(公告)号：WO2022125585A1
公开(公告)日：2022-06-16
申请号：PCT/US2021/062264
申请日：2021-12-07
申请人： THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
发明人： SORAGNI, Alice , TEBON, Peyton John , LIN, Luda , TAVANAIE, Nasrin , WANG, Bowen
IPC分类号： A61K31/335 , C12Q1/6886 , G01N33/574
摘要： The present disclosure describes a high-throughput methodology for rapid and highly personalized screenings to identify efficacious anti-tumor immunotherapy regiments. In one embodiment, therapeutic agents or a combination thereof are screened by co-culturing tumor shaped organoid extrudates with a population of immune cells taken from the same patient. Reduced tumor cell functions or increased immune cell functions in the presence of the therapeutic agents or combination thereof would identify the therapeutic agents or combination thereof for treating the tumor in the patient.

5. 发明申请

WO2020086688A1 FIDGETIN-LIKE 2 SIRNA-ENHANCED POLOXAMER-BASED HYDROGEL FOR WOUND HEALING 审中-公开
公开(公告)号：WO2020086688A1
公开(公告)日：2020-04-30
申请号：PCT/US2019/057611
申请日：2019-10-23
申请人： ALBERT EINSTEIN COLLEGE OF MEDICINE , MICROCURES, INC.
发明人： SHARP, David James , O'ROURKE, Brian , KRAMER, Adam Hildyard
IPC分类号： A61L15/10 , A61L15/26 , A61L15/44 , A61L27/12 , A61L27/18 , A61L27/54 , A61L27/56 , A61L27/58 , A61L27/60 , A61K9/06 , A61K9/127
摘要： Methods and compositions for reducing a ratio of collagen III to collagen I in wounded skin, treating wounds and accelerating healing is provided with a surfactant polymer dressing comprising FL2 siRNA, collagen and a poloxamer.

6. 发明申请

WO2020028593A1 A METHOD OF TREATING ER MUTANT EXPRESSING BREAST CANCERS WITH SELECTIVE ANDROGEN RECEPTOR MODULATORS (SARMS) 审中-公开
公开(公告)号：WO2020028593A1
公开(公告)日：2020-02-06
申请号：PCT/US2019/044550
申请日：2019-07-31
申请人： ONCTERNAL THERAPEUTICS, INC.
发明人： NARAYANAN, Ramesh , PONNUSAMY, Thamarai
IPC分类号： A61K31/167 , A61K31/277 , A61P35/00
摘要： This invention relates to the treatment of breast cancer in a subject, for example a female subject. Including methods of: treating metastatic breast cancer; refractory breast cancer; AR-positive breast cancer; AR-positive refractory breast cancer; AR-positive metastatic breast cancer; AR-positive and ER-positive breast cancer; triple negative breast cancer; advanced breast cancer; breast cancer that has failed selective estrogen receptor modulator (SERM) (tamoxifen, toremifene, raloxifene), gonadotropin-releasing hormone (GnRH) agonist (goserelin), aromatase inhibitor (AI) (letrozole, anastrozole, exemestane), cyclin-dependent kinase 4/6 (CDK 4/6) inhibitor (palbociclib (Ibrance), ribociclib (Kisqali), abemaciclib (Vorzenio)), mTOR inhibitor (everolimus), trastuzumab (Herceptin, ado-trastuzumab emtansine), pertuzumab (Perjeta), lapatinib, neratinib (Nerlynx), olaparib (Lynparza) (an inhibitor of the enzyme poly ADP ribose polymerase (PARP)), bevacizumab (Avastin), and/or fulvestrant treatments; metastasis in a subject suffering from breast cancer; HER2-positive; and/or treating a subject suffering from ER mutant expressing breast cancer, comprising administering to the subject a therapeutically effective amount of a selective androgen receptor modulator (SARM) compound.

7. 发明申请

WO2017143225A1 SYSTEM AND METHOD OF DIGITIZING PHYSICAL CURRENCY OF A CASH TRANSACTION BETWEEN A MERCHANT AND A CUSTOMER 审中-公开
标题翻译：数字化客户与客户之间现金交易实物货币的系统和方法
公开(公告)号：WO2017143225A1
公开(公告)日：2017-08-24
申请号：PCT/US2017/018426
申请日：2017-02-17
申请人： CENTS TECHNOLOGIES INC.
发明人： COHEN, Eliezer
IPC分类号： G06Q20/00
CPC分类号： G06Q20/3276 , G06Q20/06 , G06Q20/20 , G06Q20/204
摘要： Systems and methods for digitizing physical currency of a cash transaction between a merchant and a customer receive transaction data from a merchant POS device including an indication of an amount of change owed to a customer and an adjustment instruction authorizing an equivalent amount to be escrowed in a digital escrow account; send an escrow instruction enabling a transfer of the adjustment amount from a merchant account to the digital escrow account; generate an graphical symbol encoded with the adjustment instruction; send the encoded graphical symbol to the POS device for the POS device to print on a customer receipt; receive from a customer device, the adjustment instruction, wherein the graphical symbol was captured by the customer device and the adjustment instruction was decoded therefrom; and send a transfer instruction enabling transfer of the adjustment amount from the digital escrow account to a customer account.
摘要翻译：用于数字化商户与客户之间的现金交易的实际货币的系统和方法从商户POS设备接收交易数据，包括对客户欠的变化量的指示以及调整指令授权等同数额在数字代管账户中被托管; 发送允许将调整量从商家账户转移到数字代管账户的托管指令; 生成用调整指令编码的图形符号; 将编码的图形符号发送到POS设备以供POS设备在客户收据上打印; 从客户设备接收调整指令，其中图形符号被客户设备捕获并且调整指令从其解码; 并发送转账指令，以便将调整金额从数字托管账户转移到客户账户。

8. 发明申请

WO2017132661A2 G PROTEIN-COUPLED RECEPTOR (GPCR) MODULATION BY IMIPRIDONES 审中-公开
标题翻译： G蛋白偶联受体（GPCR）通过IMIPRIDONES调节
公开(公告)号：WO2017132661A2
公开(公告)日：2017-08-03
申请号：PCT/US2017/015608
申请日：2017-01-30
申请人： ONCOCEUTICS, INC.
发明人： ALLEN, Joshua E. , STOGNIEW, Martin , PRABHU, Varun Vijay
IPC分类号： C07D471/14
CPC分类号： C07D471/14
摘要： Imipridones has been found to selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and to be useful for the treatment of conditions and disorders in need of such modulation, such as cancers, psychiatric disorders, and bacterial infections. In addition, methods of identifying whether a subject having these condition, is likely to be responsive to a treatment regimen, such as administration of an imipridone, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as administration of an imipridone, monitoring, or providing a prognosis for a subject with these condition are also provided.
摘要翻译：已发现伊马立酮类选择性地调节类AG蛋白偶联受体（GPCR），例如多巴胺受体的D2样亚家族，并且可用于治疗有需要的病症和病症这种调节，如癌症，精神疾病和细菌感染。另外，提供了鉴定具有这些病症的受试者是否可能对治疗方案有反应的方法，例如施用伊吡啶酮。此外，还提供了评估治疗方案的有效性的方法，例如施用伊吡啶酮，监测或提供患有这些病症的受试者的预后。

9. 发明申请

WO2017087857A1 METHODS AND COMPOSITIONS FOR TREATING CANCER 审中-公开
标题翻译：治疗癌症的方法和组合物
公开(公告)号：WO2017087857A1
公开(公告)日：2017-05-26
申请号：PCT/US2016/062865
申请日：2016-11-18
申请人： MEMORIAL SLOAN KETTERING CANCER CENTER
发明人： SCHEINBERG, David
IPC分类号： C07K7/08 , A61K39/00 , C07K14/47
CPC分类号： A61K39/00 , A61K39/0011 , C07K14/47
摘要： This invention provides methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, by administering a combination of at least one WT1 peptide, or cytotoxic T cells (CTLs) against a WT1-expressing cancer, and at least one checkpoint inhibitor. The at least one WT1 peptide can be administered to the subject by administering one or more agents to the subject resulting in delivery of one or more WT1 peptides and induction of an immune response against the WT1-expressing cancer. Examples of these WT1 delivery agents include: (i) an isolated WT1 peptide, (ii) a nucleic acid encoding the at least one WT1 peptide, and (iii) an immune cell comprising or presenting the at least one WT1 peptide or nucleic acid encoding the at least one WT1 peptide.
摘要翻译：本发明提供了治疗，减少WT1表达癌症的发生率和诱导免疫反应的方法，其通过给予至少一种WT1肽或针对WT1的细胞毒性T细胞（CTL）的组合表达WT1的癌症和至少一种检查点抑制剂。可以通过向受试者施用一种或多种试剂给予受试者至少一种WT1肽，导致递送一种或多种WT1肽并诱导针对表达WT1的癌症的免疫应答。这些WT1递送剂的实例包括：（i）分离的WT1肽，（ii）编码所述至少一种WT1肽的核酸，和（iii）包含或呈递所述至少一种WT1肽或编码核酸的免疫细胞至少一种WT1肽。

10. 发明申请

WO2017027577A1 IMAGE GUIDED FOCUSED ULTRASOUND TREATMENT DEVICE AND AIMING APPARATUS 审中-公开
标题翻译：图像引导聚焦超声处理装置和瞄准装置
公开(公告)号：WO2017027577A1
公开(公告)日：2017-02-16
申请号：PCT/US2016/046328
申请日：2016-08-10
申请人： FUSMOBILE INC.
发明人： HANANEL, Ari , AGINSKY, Ron , MEDAN, Yoav , SALOMON, Oded , KEILMAN, George
IPC分类号： A61N7/00
CPC分类号： A61N7/00
摘要： Apparatus, methods and kits are provided for X-ray guided focused ultrasound treatment that simplify focused ultrasound treatment. The apparatus comprises an arm, a cradle, a focused ultrasound (FUS) transducer having a central axis that is affixed in to the cradle and configured to transmit an ultrasound therapeutic energy beam to a treatment location within a patient and an imaging workstation connected to an X-ray imaging unit. The FUS is further connected to a controller to control application of the FUS. The kits are utilizing coupling member (s).
摘要翻译：提供了用于X射线引导聚焦超声治疗的装置，方法和试剂盒，其简化了聚焦超声处理。该装置包括臂，支架，聚焦超声（FUS）换能器，其具有固定在托架中的中心轴并且被配置为将超声治疗能量束传送到患者内的治疗位置，以及连接到患者的成像工作站 X射线成像单元。 FUS还连接到控制器以控制FUS的应用。这些套件正在利用联接构件。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式